Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
2002 5
2003 8
2004 3
2005 3
2006 2
2007 2
2008 1
2009 1
2010 1
2011 1
2012 4
2014 2
2015 1
2020 2
2021 4
2022 4
2023 5
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19 research: promising tracks leading to uro-oncology.
Tamás F, Tibor S, Anita C, Boris H, Péter N. Tamás F, et al. Int Urol Nephrol. 2020 Jun;52(6):995-997. doi: 10.1007/s11255-020-02490-2. Epub 2020 May 11. Int Urol Nephrol. 2020. PMID: 32394243 Free PMC article. No abstract available.
Defining oligometastatic state in uro-oncological cancers.
Fazekas T, Miszczyk M, Matsukawa A, Nyirády P, Shariat SF, Rajwa P. Fazekas T, et al. Curr Opin Urol. 2024 Jul 1;34(4):261-265. doi: 10.1097/MOU.0000000000001184. Epub 2024 May 2. Curr Opin Urol. 2024. PMID: 38704827 Review.
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Széles Á, Fazekas T, Váncsa S, Váradi M, Kovács PT, Krafft U, Grünwald V, Hadaschik B, Csizmarik A, Hegyi P, Váradi A, Nyirády P, Szarvas T. Széles Á, et al. Among authors: fazekas t. Cancer Immunol Immunother. 2023 May;72(5):1061-1073. doi: 10.1007/s00262-022-03328-9. Epub 2022 Nov 16. Cancer Immunol Immunother. 2023. PMID: 36385210 Free PMC article. Review.
Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis.
Matsukawa A, Yanagisawa T, Bekku K, Kardoust Parizi M, Laukhtina E, Klemm J, Chiujdea S, Mori K, Kimura S, Fazekas T, Miszczyk M, Miki J, Kimura T, Karakiewicz PI, Rajwa P, Shariat SF. Matsukawa A, et al. Among authors: fazekas t. Eur Urol Oncol. 2024 Jan 4:S2588-9311(23)00292-4. doi: 10.1016/j.euo.2023.12.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38182488 Free article. Review.
Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
Fazekas T, Széles ÁD, Teutsch B, Csizmarik A, Vékony B, Kói T, Ács N, Hegyi P, Hadaschik B, Nyirády P, Szarvas T. Fazekas T, et al. Eur Urol Oncol. 2024 Jun;7(3):365-375. doi: 10.1016/j.euo.2023.09.001. Epub 2023 Sep 16. Eur Urol Oncol. 2024. PMID: 37722977 Free article. Review.
Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis.
Fazekas T, Shim SR, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas JG, Gandaglia G, Szarvas T, Schoots IG, van den Bergh RCN, Leapman MS, Nyirády P, Shariat SF, Rajwa P. Fazekas T, et al. JAMA Oncol. 2024 Apr 5:e240734. doi: 10.1001/jamaoncol.2024.0734. Online ahead of print. JAMA Oncol. 2024. PMID: 38576242
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
Váradi M, Horváth O, Módos O, Fazekas T, Grunewald CM, Niegisch G, Krafft U, Grünwald V, Hadaschik B, Olah C, Maráz A, Furka A, Szűcs M, Nyirády P, Szarvas T. Váradi M, et al. Among authors: fazekas t. Sci Rep. 2023 Oct 13;13(1):17378. doi: 10.1038/s41598-023-44103-9. Sci Rep. 2023. PMID: 37833455 Free PMC article.
51 results